Effect of Shexiang Baoxin Pill () in Alleviating Early Hypertensive Renal Injury in Rats.

Chin J Integr Med

Department of Geriatric Nephrology, Chinese PLA General Hospital, Beijing, 100853, China.

Published: January 2021

Objective: To investigate the effect of Shexiang Baoxin Pill (, SBP) on early hypertensive renal injury in rats and to explore the possible mechanism.

Methods: Twelve-week-old spontaneous hypertensive rats (SHRs) with high-salt diet (dietary containing 8% NaCl) were randomized into the SBP group [40 mg/(kg·d)], losartan potassium group [20 mg/(kg·d)] and saline group by stratified random sampling method, 12 in each group. Blood pressure and urea albumin creatinine ratio were measured. After 10 weeks, the expression levels of serum creatinine (Scr), hypersensitive C-reactive protein (hs-CRP), interleukin (IL)-1 β, IL-6, tumor necrosis factor α (TNF-α), and transforming growth factor β (TGF-β) in serum were assessed. Kidney pathology periodate-schiff staining was performed. Semi-quantitative count of macrophage infiltration was determined by immunochemistry of CD68 staining. Real-time quantitative polymerase chain reaction and Western blot were performed to examine the mRNA and protein expressions of Toll-like receptor 4 (TLR4), nuclear factor κB (NF-κB), monocyte chemokine peptide (MCP-1), inducible nitric oxide synthase (iNOS), and arginase-1 (Arg-1).

Results: SBP did not affect the mortality of SHR (P<0.05). SBP significantly reduced the level of elevated blood pressure of SHRs, but the effect was less significantly than that of losartan potassium. SBP decreased urine protein (P<0.01) and the expression levels of IL-1 β, IL-6, TNF-α, and TGF-β in serum. The 22-week-old SHRs showed mild proliferation of glomerular endothelial cells, glomerular ischemic lesions, inflammatory cell infiltration in renal tubular interstitium and arteriosclerosis. Both SBP and losartan potassium had alleviated renal pathological change, and significantly reduced the infiltration of macrophage (P<0.05, P<0.01). SBP and losartan potassium decreased the expressions of TLR4, NF-κB, MCP-1, iNOS, and Arg-1.

Conclusion: SBP significantly modified the early hypertensive renal injury by reducing inflammation, and the effect was similar to losartan potassium.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11655-019-3162-zDOI Listing

Publication Analysis

Top Keywords

shexiang baoxin
8
baoxin pill
8
early hypertensive
8
hypertensive renal
8
renal injury
8
injury rats
8
pill alleviating
4
alleviating early
4
rats objective
4
objective investigate
4

Similar Publications

Ethnopharmacological Relevance: Shexiang Baoxin Pill (MUSKARDIA), a traditional Chinese patent medicine, plays a crucial role in both preventing and treating diverse cardiovascular diseases, including coronary heart disease, myocardial infarction (MI), and heart failure. Preclinical research has demonstrated that the cardioprotective effects of MUSKARDIA are achieved through multiple pathways, such as enhancing coronary artery dilation, fostering new blood vessel growth, reducing inflammation and oxidative stress, improving lipid metabolism, and protecting vascular endothelium.

Aim Of The Study: This subgroup analysis aimed to evaluate the efficacy and safety of Shexiang Baoxin Pill (MUSKARDIA) plus optimal medical therapy (OMT) across different weight categories in treating stable coronary artery disease (CAD).

View Article and Find Full Text PDF

Integrated metabolomics and network pharmacology to reveal the mechanisms of Shexiang Baoxin pill against atherosclerosis.

Phytomedicine

December 2024

Department of Cardiology, The Affiliated Hospital of Qingdao University, Qingdao, China; Department of Cardiology, The Affiliated Cardiovascular Hospital of Qingdao University, Qingdao, China. Electronic address:

Background: Atherosclerosis is a disease marked by the development of lipid lesions within the endothelium and continues to be a prominent contributor to global mortality. Shexiang Baoxin pill (SBP) has been employed in the management of numerous cardiovascular diseases, but the complex mechanisms by which it operates remain obscure. This research was conducted to determine the potential impact of SBP on atherosclerosis and the underlying regulatory mechanism involved.

View Article and Find Full Text PDF

Background: Chinese patent medicines (CPMs) are widely used in China as an adjuvant treatment in dilated cardiomyopathy with heart failure (DCM-HF). However, comprehensive and systematic evidence supporting the beneficial effects of CPMs combined with current complementary and alternative medicine (CAM) treatments against DCM-HF was limited. This network meta-analysis (NMA) aimed to assess and rank the relative efficacy of eight different CPMs for DCM-HF.

View Article and Find Full Text PDF
Article Synopsis
  • A network meta-analysis was conducted to evaluate the effectiveness and safety of various Chinese patent medicines for treating chronic pulmonary heart disease, analyzing data from numerous databases including CNKI, PubMed, and Cochrane Library, up to December 2023.
  • The analysis included 95 randomized controlled trials (RCTs) with a total of 8,787 patients and assessed multiple Chinese patent medicines, focusing on metrics like cardiac function, forced expiratory volume, and partial pressure of gases in the blood.
  • Top-performing treatments combined Chinese medicines with conventional western medicines, including Wenxin Granules, Tongxinluo Capsules, and Qishen Yiqi Dropping Pills for overall efficacy and improvements in respiratory function.
View Article and Find Full Text PDF

Background: Patients with myocardial infarction (MI) frequently experience a heightened incidence of depression, thereby increasing the risk of adverse cardiovascular events. Consequently, early detection and intervention in depressive symptoms among patients with MI are imperative. Shexiang Baoxin Pills (SBP), a Chinese patent medicine employed for the treatment of MI, exhibits diverse mechanisms targeting this condition.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!